0
0
1/17/23 at 3:09pm
Organization
Targetedonc.com
Author
Nichole Tucker
36 words
0
Comments
Months after the FDA granted accelerated approval to dostarlimab for this rectal cancer indication, phase 2 data have confirmed its efficacy and safety.
You are the first to view
https://www.targetedonc.com/view/dostarlimab-benefit-confirmed-for-patients-with-mrd-locally-advanced-rectal-cancer
Create an account
or login to join the discussion